Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program

Following disappointing Phase II results, Xoma will not conduct future trials with the bactericidal/permeability-increasing protein derivative XMP.629, its lead candidate. Earlier-stage BPI-derived products are under evaluation.